Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026

HONG KONG, April 6, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label,…

More Stories

Amazon worker robbed: NYPD

Police are on the lookout for an armed man who held up a delivery worker in Rosedale, within the 116th Precinct, and stole packages from inside his vehicle on April 1.The Amazon worker, 43, was outside a residence on 241st…

Read More »